KR102236391B1 - Personal cleansing composition comprising Magnolia officinalis extract - Google Patents
Personal cleansing composition comprising Magnolia officinalis extract Download PDFInfo
- Publication number
- KR102236391B1 KR102236391B1 KR1020140109935A KR20140109935A KR102236391B1 KR 102236391 B1 KR102236391 B1 KR 102236391B1 KR 1020140109935 A KR1020140109935 A KR 1020140109935A KR 20140109935 A KR20140109935 A KR 20140109935A KR 102236391 B1 KR102236391 B1 KR 102236391B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- oil
- human body
- extract
- cleaning
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 239000000284 extract Substances 0.000 title claims abstract description 69
- 241001673966 Magnolia officinalis Species 0.000 title 1
- 239000000194 fatty acid Substances 0.000 claims abstract description 72
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 70
- 229930195729 fatty acid Natural products 0.000 claims abstract description 70
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 59
- 238000004140 cleaning Methods 0.000 claims abstract description 43
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 29
- 239000003205 fragrance Substances 0.000 claims abstract description 15
- HGASFNYMVGEKTF-UHFFFAOYSA-N octan-1-ol;hydrate Chemical compound O.CCCCCCCCO HGASFNYMVGEKTF-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000005192 partition Methods 0.000 claims abstract description 5
- 239000010903 husk Substances 0.000 claims abstract description 4
- 238000001179 sorption measurement Methods 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 17
- 235000019482 Palm oil Nutrition 0.000 claims description 12
- 239000002540 palm oil Substances 0.000 claims description 12
- 239000004359 castor oil Substances 0.000 claims description 11
- 235000019438 castor oil Nutrition 0.000 claims description 9
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 8
- 239000003925 fat Substances 0.000 claims description 7
- 235000019197 fats Nutrition 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- 239000003346 palm kernel oil Substances 0.000 claims description 6
- 235000019865 palm kernel oil Nutrition 0.000 claims description 6
- 241000186245 Corynebacterium xerosis Species 0.000 claims description 5
- 241000186427 Cutibacterium acnes Species 0.000 claims description 5
- 239000003760 tallow Substances 0.000 claims description 5
- 239000005642 Oleic acid Substances 0.000 claims description 4
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 4
- 239000003517 fume Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229940055019 propionibacterium acne Drugs 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- 239000005639 Lauric acid Substances 0.000 claims description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 235000012343 cottonseed oil Nutrition 0.000 claims description 3
- 239000002385 cottonseed oil Substances 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 235000020778 linoleic acid Nutrition 0.000 claims description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 235000021313 oleic acid Nutrition 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 235000019774 Rice Bran oil Nutrition 0.000 claims description 2
- 235000019485 Safflower oil Nutrition 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 239000010495 camellia oil Substances 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 235000015277 pork Nutrition 0.000 claims description 2
- 239000008165 rice bran oil Substances 0.000 claims description 2
- 235000005713 safflower oil Nutrition 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 239000008159 sesame oil Substances 0.000 claims description 2
- 235000011803 sesame oil Nutrition 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 239000010698 whale oil Substances 0.000 claims description 2
- 206010000496 acne Diseases 0.000 abstract description 38
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 31
- 241000894006 Bacteria Species 0.000 abstract description 21
- 208000035985 Body Odor Diseases 0.000 abstract description 15
- 206010040904 Skin odour abnormal Diseases 0.000 abstract description 13
- 244000005700 microbiome Species 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 3
- 230000036559 skin health Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 27
- 230000000694 effects Effects 0.000 description 25
- 235000019645 odor Nutrition 0.000 description 23
- -1 acyl ceramide Chemical compound 0.000 description 21
- 238000012360 testing method Methods 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 239000000344 soap Substances 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 10
- 210000003780 hair follicle Anatomy 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 9
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 6
- 239000002736 nonionic surfactant Substances 0.000 description 6
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229960003237 betaine Drugs 0.000 description 5
- 239000003974 emollient agent Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000003352 sequestering agent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 210000004243 sweat Anatomy 0.000 description 5
- 229960003500 triclosan Drugs 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 239000002280 amphoteric surfactant Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- UAZLASMTBCLJKO-UHFFFAOYSA-N 2-decylbenzenesulfonic acid Chemical compound CCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O UAZLASMTBCLJKO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- 241000186216 Corynebacterium Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001447 alkali salts Chemical class 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 238000000194 supercritical-fluid extraction Methods 0.000 description 3
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 3
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 3
- 229960001325 triclocarban Drugs 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 2
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- QZXSMBBFBXPQHI-UHFFFAOYSA-N N-(dodecanoyl)ethanolamine Chemical compound CCCCCCCCCCCC(=O)NCCO QZXSMBBFBXPQHI-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 2
- 241000219784 Sophora Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 2
- FKWGCEDRLNNZOZ-GFCCVEGCSA-N Xanthorrhizol Chemical compound CC(C)=CCC[C@@H](C)C1=CC=C(C)C(O)=C1 FKWGCEDRLNNZOZ-GFCCVEGCSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011538 cleaning material Substances 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 2
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 235000020744 piper nigrum extract Nutrition 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229940077082 red pepper extract Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 244000005714 skin microbiome Species 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000010677 tea tree oil Substances 0.000 description 2
- 229940111630 tea tree oil Drugs 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- MTJZWYHTZFVEGI-INIZCTEOSA-N (2s)-2-(tetradecanoylamino)pentanedioic acid Chemical compound CCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O MTJZWYHTZFVEGI-INIZCTEOSA-N 0.000 description 1
- VQQFQUXKIKUEIU-DFWYDOINSA-N (2s)-5-oxopyrrolidine-2-carboxylic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)[C@@H]1CCC(=O)N1 VQQFQUXKIKUEIU-DFWYDOINSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- FCAXDVKLWVSHGT-KVVVOXFISA-N (z)-docos-13-enoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O FCAXDVKLWVSHGT-KVVVOXFISA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- XPALGXXLALUMLE-UHFFFAOYSA-N 2-(dimethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(N(C)C)C(O)=O XPALGXXLALUMLE-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- LNCJHVLXANMHHD-UHFFFAOYSA-N 2-[2-heptadecyl-1-(2-hydroxyethyl)-4,5-dihydroimidazol-1-ium-1-yl]acetate Chemical compound CCCCCCCCCCCCCCCCCC1=NCC[N+]1(CCO)CC([O-])=O LNCJHVLXANMHHD-UHFFFAOYSA-N 0.000 description 1
- JFWPGOZRLLZFPL-RMRYJAPISA-N 2-[bis(2-hydroxyethyl)amino]ethanol;(2s)-2-(hexadecanoylamino)butanedioic acid Chemical compound OCCN(CCO)CCO.OCCN(CCO)CCO.CCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CC(O)=O JFWPGOZRLLZFPL-RMRYJAPISA-N 0.000 description 1
- ZCOLQXXFCPFSNU-UHFFFAOYSA-N 2-[methyl(tetradecanoyl)amino]ethanesulfonic acid;sodium Chemical compound [Na].CCCCCCCCCCCCCC(=O)N(C)CCS(O)(=O)=O ZCOLQXXFCPFSNU-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241001456553 Chanodichthys dabryi Species 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N N-methylaminoacetic acid Natural products C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001464887 Parvimonas micra Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 235000019820 disodium diphosphate Nutrition 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- GYQBBRRVRKFJRG-UHFFFAOYSA-L disodium pyrophosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940071085 lauroyl glutamate Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- ONQDVAFWWYYXHM-UHFFFAOYSA-M potassium lauryl sulfate Chemical compound [K+].CCCCCCCCCCCCOS([O-])(=O)=O ONQDVAFWWYYXHM-UHFFFAOYSA-M 0.000 description 1
- 229940116985 potassium lauryl sulfate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 229940071136 stearoyl glutamate Drugs 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229940117986 sulfobetaine Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- KWXLCDNSEHTOCB-UHFFFAOYSA-J tetrasodium;1,1-diphosphonatoethanol Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P(=O)([O-])C(O)(C)P([O-])([O-])=O KWXLCDNSEHTOCB-UHFFFAOYSA-J 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 238000010267 two-fold dilution method Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- FKWGCEDRLNNZOZ-UHFFFAOYSA-N xanthorrhizol Natural products CC(C)=CCCC(C)C1=CC=C(C)C(O)=C1 FKWGCEDRLNNZOZ-UHFFFAOYSA-N 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Cosmetics (AREA)
- Detergent Compositions (AREA)
Abstract
본 발명은 후박 추출물을 포함하는 인체 세정용 조성물에 관한 것으로, 보다 구체적으로는 후박 추출물, 지방산, 및 ClogP(옥탄올-물 분배계수, Octanol-water partition coefficient) 값이 3 이상인 향료를 포함하는 인체 세정용 조성물에 관한 것이다. 본 발명의 인체 세정용 조성물은 체취 유발 미생물들의 증식 억제 및 제거 효과가 탁월하고, 여드름균에 대한 항균력이 우수하여 여드름 치료에 효과적이며, 잔향성이 우수하다. 또한, 본 발명의 인체 세정용 조성물은 천연성분으로 구성되어 인체에 안전하므로, 연령에 관계 없이 피부 건강 유지 및 개선을 위해 사용될 수 있다.The present invention relates to a composition for cleansing the human body comprising a husk extract, more specifically, a human body comprising a husk extract, a fatty acid, and a fragrance having a ClogP (octanol-water partition coefficient) value of 3 or more. It relates to a cleaning composition. The composition for cleaning the human body of the present invention is excellent in inhibiting and removing body odor-causing microorganisms, has excellent antibacterial activity against acne bacteria, is effective in treating acne, and has excellent reverberation properties. In addition, since the composition for cleaning the human body of the present invention is made of natural ingredients and is safe for the human body, it can be used for maintaining and improving skin health regardless of age.
Description
본 발명은 후박 추출물을 포함하는 인체 세정용 조성물에 관한 것으로, 보다 구체적으로는 후박 추출물을 포함함으로써 여드름을 유발하는 주요 미생물에 대한 항균 효과가 우수하며 잔향성이 우수한 인체 세정용 조성물에 관한 것이다.The present invention relates to a composition for cleaning the human body comprising a Hubak extract, and more particularly, to a composition for cleaning the human body having excellent antibacterial effect against major microorganisms causing acne and excellent reverberation by including the Hubak extract.
피부질환 중 본 발명의 관심인 체취와 여드름의 발병 및 악화는 미생물 특히, 세균과 밀접한 관계가 있다. 먼저 체취는 인체에서 분비된 에크린땀(Eccrine sweat), 아포크린땀(Apocrine sweat), 피지, 또는 오염물을 미생물 등이 분해시킴으로써 발생하게 된다. 처음 분비된 에크린땀이나 아포크린땀은 무취이지만, 피부 표피, 털, 땀구멍 등에 상재하는 여러 미생물, 특히 체취와 관련된 미생물들의 작용으로 사람에게 불쾌감을 주는 액취, 족취, 두취 등의 체취를 유발하게 된다.Among skin diseases, the onset and exacerbation of body odor and acne, which are of interest in the present invention, are closely related to microorganisms, especially bacteria. First, body odor is generated by microorganisms, etc., decomposing ecrine sweat, apocrine sweat, sebum, or contaminants secreted from the human body. The first secreted ecrine sweat or apocrine sweat is odorless, but the action of various microorganisms residing in the epidermis, hair, and pores of the skin, especially those related to body odor, causes unpleasant body odors, such as odor, foot odor, and odor.
피부에는 수많은 상재균이 존재하는데, 대표적인 것으로는 포도상구균인 스타필로 코커스(Staphylococcus), 구균인 마이크로코커스(Micrococcus), 코리네 박테리움(Corynebacterium), 피이티로스포룸(Pityrosporum), 또는 대장균(E.coli) 등이 있으며 특히, 코리네박테리움이 코를 자극하는 불쾌취로 강한 냄새를 내는 사람에게서 많이 발견되는 것으로 알려져 있다. 다음으로, 여드름은 주로 사춘기 연령대와 같은 젊은 남녀의 얼굴이나 가슴, 목 부위에 발생하는 모 피지선의 만성 염증성 질환으로서, 면포(comedone), 구진(papule), 농포(pustule), 낭종, 또는 결절을 형성하며, 심한 경우에는 반흔을 남길 수 있는 병변이다.Skin, to the number of flora present, typical to the Staphylococcus aureus is Staphylococcus (Staphylococcus), Streptococcus micro Rhodococcus (Micrococcus), Corynebacterium (Corynebacterium), P ET Los Forum (Pityrosporum), or E. coli (E .coli ), and in particular, Corynebacterium is known to be found in many people with strong odor due to an unpleasant odor that irritates the nose. Next, acne is a chronic inflammatory disease of the furry sebaceous glands that occurs mainly on the face, chest, and neck of young men and women such as puberty, and it is known as comedones, papules, pustules, cysts, or nodules. It forms, and in severe cases, is a lesion that can leave a scar.
여드름의 발생기전은 아직까지 확실하게 규명되어 있지는 않으나, 대체적으로 1) 여드름균의 증식, 2) 피지분비의 증가, 3) 비정상적으로 증가된 모낭벽 과각화, 및 4) 기타 염증요인의 네 가지 요소로 정리될 수 있으며, 여드름 치료 방법도 이러한 원인들을 제거하는데 그 원칙을 두고 있다.Although the mechanism of occurrence of acne is not yet clearly identified, there are generally four factors: 1) proliferation of acne bacteria, 2) increase in sebum secretion, 3) abnormally increased hair follicle wall hyperkeratosis, and 4) other inflammatory factors. It can be summarized as, and acne treatment methods are also based on the principle of eliminating these causes.
여드름 환자의 피지 내 지방성분에는 변화가 생기는데, 아실세라마이드(acyl ceramide)의 리놀레산(linoleic acid)과 콜레스테롤(cholesterol)의 함량이 감소되고 스쿠알렌(squalene)과 지방산의 함량이 증가한다. 이러한 지방 조성의 변화로 인하여 모낭 내의 콜레스테롤과 콜레스테롤설페이트(cholesterol sulfate) 간의 불균형이 초래되고, 이에 따라 모낭 내 각질 형성세포 사이의 결합이 증진되어 모낭 정체 과각화증(follicular retention hyperkeratosis)이 초래된다. 그 결과, 모낭 내에 정체된 피지는 모낭을 막아 공기의 순환을 차단하게 됨으로써 모낭 내부는 모낭 내에 상주하는 혐기성 세균인 프로피오니박테리움아크네스(Propionibacterium acnes)가 잘 자랄 수 있는 환경이 된다. 이 여드름균은 지방분해효소와 화학 주성인자를 분비하여 지방산을 만들어 백혈구가 모낭 주위에 모이게 하며, 이들이 모낭 벽을 자극하고 파괴하여 모낭 내용물이 진피 내로 유출됨에 따라 염증반응이 일어나게 된다.There is a change in the fat content of the sebum of acne patients, and the content of linoleic acid and cholesterol in acyl ceramide decreases, and the content of squalene and fatty acids increases. This change in fat composition causes an imbalance between cholesterol in the hair follicle and cholesterol sulfate, and thus, the binding between keratinocytes in the hair follicle is enhanced, resulting in follicular retention hyperkeratosis. As a result, the sebum stagnated in the hair follicle blocks the hair follicle and blocks air circulation, so that the inside of the hair follicle becomes an environment in which Propionibacterium acnes, an anaerobic bacterium residing in the hair follicle, can grow well. These acne bacteria secrete lipolytic enzymes and chemotactic factors to make fatty acids, causing white blood cells to gather around the hair follicles, and they stimulate and destroy the walls of the hair follicles, causing an inflammatory reaction as the hair follicle contents flow into the dermis.
이와 같은 체취와 여드름 균의 번식을 억제하는 항균물질은 다수 알려져 있는데, 트리클로산, 트리클로카반(triclocarban), 염화벤잘코늄(benzalkonium chloride), 염화벤제토늄(benzethonium chloride), 염산클로르헥시딘(chlorhexidine hydrochloride), 글루콘산클로르헥시딘 (chlorhexidine gluconate),파네졸(fanesol), 쿠퍼글루코네이트(copper gluconate), 또는 징크 글루코네이트(zinc gluconate); 티트리오일(tea tree oil), 정향, 회향, 박하, 또는 고삼 등의 식물오일 또는 식물추출물; 또는 키틴 또는 그 유도체 등이 있다.There are many known antibacterial substances that inhibit such body odor and the reproduction of acne bacteria, such as triclosan, triclocarban, benzalkonium chloride, benzethonium chloride, chlorhexidine hydrochloride, and glue. Chlorhexidine gluconate, fanesol, copper gluconate, or zinc gluconate; Plant oils or plant extracts such as tea tree oil, cloves, fennel, mint, or sophora; Or chitin or a derivative thereof.
그러나, 이러한 물질들은 소량만으로는 여드름균에 대한 충분한 항균효과를 나타내지 못할 뿐만 아니라 과량 도포 시 피부발적 또는 피부건조증 등의 부작용이 발생할 우려가 있으며, 트리클로산, 트리클로카반 등 대중화 되어있는 항균물질은 장기간 사용할 경우 피부내 병원균에 대한 내성을 증가시키고 내분비계 호르몬 교란 및 발암성에 대한 가능성이 보고되고 있으며, 세정제품에 대해서는 피부 흡착력이 부족하여 충분한 항균효과를 발휘하기 어렵다.However, these substances may not exhibit sufficient antibacterial effect against acne bacteria with only a small amount, and there is a risk of side effects such as skin redness or dry skin when applied in excessive amounts, and popular antibacterial substances such as triclosan and triclocarban are used for a long period of time. It increases the resistance to pathogens in the skin, and the possibility of disturbance of endocrine hormones and carcinogenicity has been reported, and it is difficult to exert sufficient antibacterial effect due to lack of skin adsorption for cleaning products.
따라서 본 발명이 해결하고자 하는 과제는 피부 상재균을 포함하는 체취균과 여드름균에 강력한 항균 효과를 나타내며, 세정 후에도 피부 흡착 정도가 우수하여 소량 사용 가능하며, 피부에 대한 부작용이 적은 인체 세정용 조성물을 제공하는 것이다.Therefore, the problem to be solved by the present invention is a composition for human body cleaning that exhibits a strong antibacterial effect on body odors including skin flora and acne bacteria, and has excellent skin adsorption even after washing, so that it can be used in small amounts and has less side effects on the skin. Is to provide.
상기 과제를 해결하기 위하여, 본 발명은 후박 추출물, 지방산, 및 하기 수학식에 의한 ClogP(옥탄올-물 분배계수, Octanol-water partition coefficient) 값이 3 이상인 향료를 포함하는 인체 세정용 조성물을 제공한다.In order to solve the above problems, the present invention provides a composition for human body cleaning comprising a flavoring having a ClogP (octanol-water partition coefficient) value of 3 or more according to the following equation: do.
[수학식 1][Equation 1]
본 발명의 발명자들은 피부 위생 증진, 불쾌한 체취 제거, 및 여드름 개선 효과가 우수한 인체 세정용 조성물을 개발하기 위해 연구하던 중, 후박 추출물이 체취 및 여드름을 유발하는 미생물들에 강력한 항균 효과를 갖는 것을 발견하였다. 또한, 인체 세정용 조성물에 후박 추출물과 함께 지방산 및 ClogP 값이 3 이상인 항료를 함께 함유하는 경우, 후박 추출물의 피부 흡착을 증대시키며 세정 후에도 잔향성이 우수한 놀라운 사실을 발견하여 본 발명을 완성하였다.
The inventors of the present invention were researching to develop a composition for cleaning the human body with excellent skin hygiene enhancement, unpleasant body odor removal, and acne improvement effects, and found that the extract has a strong antibacterial effect against microorganisms that cause body odor and acne. I did. In addition, when the composition for cleaning the human body contains a fatty acid and a perfume having a ClogP value of 3 or more together with the extract of Hubak extract, it was found that the skin adsorption of the Hubak extract was increased and the reverberation property was excellent even after washing, thereby completing the present invention.
본 발명에서 상기 후박 추출물은 후박 나무의 다양한 기관 또는 부분, 즉, 잎, 꽃, 열매, 줄기, 뿌리, 가지, 또는 껍질 등으로부터 추출하여 얻을 수 있다. 상기 추출물은 본 발명이 속하는 기술분야에서 통상적으로 사용되는 추출 방법으로 물 또는 유기용매를 이용한 용매 추출법, 초임계 추출법, 수증기 증류법, 또는 초음파 추출법 등에 의해 얻어질 수 있다. 바람직하게는 상기 추출물은 이산화탄소를 이용한 초임계 추출법을 이용하여 추출될 수 있다.In the present invention, the Hubak extract may be obtained by extracting from various organs or parts of the Hubak tree, that is, leaves, flowers, fruits, stems, roots, branches, or bark. The extract may be obtained by a solvent extraction method using water or an organic solvent, a supercritical extraction method, a steam distillation method, or an ultrasonic extraction method as an extraction method commonly used in the technical field to which the present invention belongs. Preferably, the extract may be extracted using a supercritical extraction method using carbon dioxide.
상기 용매 추출법에 사용될 수 있는 유기용매로는 기술분야에서 통상적으로 사용되는 유기용매가 사용될 수 있으며, 메탄올, 에탄올, 이소프로필알코올, 및 부탄올 등의 저급 알코올; 글리세론, 에틸렌글리콜, 프로필렌글리콜, 및 1,3-부틸렌글리콜 등의 다가 알코올; 및 석유에테르, 메틸아세테이트, 에틸아세테이트, 벤젠, 헥산, 메틸렌클로라이드, 디에틸에테르, 디클로메탄, 및 클로로포름 등의 탄화수소계 용매 등으로 이루어진 군에서 선택된 1종 이상이 사용될 수 있다.As the organic solvent that can be used in the solvent extraction method, an organic solvent commonly used in the technical field may be used, and lower alcohols such as methanol, ethanol, isopropyl alcohol, and butanol; Polyhydric alcohols such as glyceron, ethylene glycol, propylene glycol, and 1,3-butylene glycol; And hydrocarbon-based solvents such as petroleum ether, methyl acetate, ethyl acetate, benzene, hexane, methylene chloride, diethyl ether, dichloromethane, and chloroform.
상기 후박 추출물은 용매 추출법에 의한 액체 상태의 추출물 또는 이를 용매에 희석한 것이 사용되거나, 이산화탄소를 이용한 초임계 추출물이 사용되거나, 이들을 분말화한 것이 사용될 수도 있다. 상기 분말화는 진공건조, 동결건조, 또는 분무건조 등의 당업계에 공지된 통상의 방법으로 행해질 수 있다. 바람직하게는 상기 후박 추출물은 이산화탄소를 이용한 초임계 추출물을 사용할 수 있다.The extract may be a liquid extract obtained by a solvent extraction method, or a solution obtained by diluting it in a solvent, a supercritical extract using carbon dioxide, or a powdered extract thereof. The powdering may be performed by a conventional method known in the art such as vacuum drying, freeze drying, or spray drying. Preferably, the thick bark extract may be a supercritical extract using carbon dioxide.
본 발명의 상기 추출물은 상기한 추출 용매뿐만 아니라, 통상적인 정제과정을 거친 추출물도 포함한다. 구체적으로, 본 발명의 추출물은 추출용매에 의한 추출 후 정제과정, 예를 들어 일정한 분자량으로 컷-오프값을 갖는 여과막을 이용한 막 분리, 크기, 전하, 소수성, 또는 친화성 등에 따른 분리를 위한 다양한 크로마토그래피에 의한 분리 등의 정제 과정을 추가적으로 실시하여 사용될 수 있다.The extract of the present invention includes not only the extraction solvent described above, but also an extract that has undergone a conventional purification process. Specifically, the extract of the present invention is a purification process after extraction with an extraction solvent, for example, membrane separation using a filtration membrane having a cut-off value with a certain molecular weight, various for separation according to size, charge, hydrophobicity, or affinity, etc. It may be used by additionally performing a purification process such as separation by chromatography.
본 발명에서 상기 후박 추출물은 조성물 총 중량 대비 0.01~2 중량%, 바람직하게는 0.02~1.5 중량%, 더욱 바람직하게는 0.03~0.8 중량% 포함될 수 있다. 상기 후박 추출물의 함량이 0.01 중량% 미만이면 항균력이 나타나지 않고, 2 중량%을 초과하면 경제성 및 제형 안정성이 좋지 않아 바람직하지 않다.
In the present invention, the fugitive extract may be included in an amount of 0.01 to 2% by weight, preferably 0.02 to 1.5% by weight, and more preferably 0.03 to 0.8% by weight, based on the total weight of the composition. If the content of the extract is less than 0.01% by weight, antibacterial activity does not appear, and if it exceeds 2% by weight, economy and formulation stability are poor, which is not preferable.
본 발명의 조성물에서 상기 지방산은 동물 유지 또는 식물 유지에서 유도된 라우르산, 미리스트산, 팔미트산, 스테아르산, 올레산, 및 리놀레산 등을 포함하는 C8~20 카르복실산; 팜유, 팜핵유, 대두유, 유채유, 옥수수유, 평지유, 해바라기유, 홍화유, 면실유, 참기름, 미강유, 동백유, 피마자유, 올리브유, 및 야자유 등을 포함하는 식물성 유지로부터 유래된 지방산; 우지, 돈지, 양지, 어유, 고래기름, 및 다랑어 기름 등을 포함하는 동물성 유지로부터 유래된 지방산(예를 들어, 탈로우산(tallow acid)); 지방 알코올, 광유, 및 파라핀 등으로 이루어진 군에서 선택된 1종 이상이 사용될 수 있으나, 이에 한정되는 것은 아니다. 바람직하게는 지방산으로 팜유 또는 팜핵유로부터 유래된 팜유 지방산, 팜핵유 지방산, 또는 우지 등으로부터 유래된 탈로우산(tallow acid)을 사용할 수 있다.
In the composition of the present invention, the fatty acid may include C8-20 carboxylic acids including lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, and linoleic acid derived from animal fat or vegetable fats and oils; Fatty acids derived from vegetable oils, including palm oil, palm kernel oil, soybean oil, rapeseed oil, corn oil, rapeseed oil, sunflower oil, safflower oil, cottonseed oil, sesame oil, rice bran oil, camellia oil, castor oil, olive oil, and palm oil; Fatty acids derived from animal fats and oils (eg, tallow acid), including tallow, pork fat, sunny fat, fish oil, whale oil, and tuna oil; At least one selected from the group consisting of fatty alcohol, mineral oil, and paraffin may be used, but is not limited thereto. Preferably, as the fatty acid, palm oil fatty acid derived from palm oil or palm kernel oil, palm kernel oil fatty acid, or tallow acid derived from tallow, etc. may be used.
본 발명에서 지방산은 조성물 중 항균활성을 가지는 후박 추출물에 결합하여 피부에 흡착을 증대시키고 우수한 에몰리언트 효과를 부여하기 위해, 조성물 총 중량 대비 1~30 중량%, 바람직하게는 2~15 중량%, 보다 바람직하게는 3~7 중량% 포함될 수 있다. 지방산의 함량이 1 중량% 미만이면 피부 흡착효과가 현저히 떨어지며, 30 중량%를 초과하면 사용감 및 안정성이 좋지 않아 바람직하지 않다.
In the present invention, the fatty acid is bound to the extract having antimicrobial activity in the composition to increase adsorption to the skin and impart an excellent emollient effect, in order to provide an excellent emollient effect, 1 to 30% by weight, preferably 2 to 15% by weight, more Preferably it may be included in 3 to 7% by weight. If the fatty acid content is less than 1% by weight, the skin adsorption effect is remarkably deteriorated, and if it exceeds 30% by weight, the feeling and stability are not good, which is not preferable.
본 발명의 조성물에서 ClogP 값이 3 이상인 향료는 세정 후에도 피부 잔류성이 높아 잔향성이 우수하다. 본 발명의 조성물에서 ClogP 값이 3 이상인 향료는 조성물 총 중량 대비 0.1~5 중량%, 바람직하게는 0.5~3 중량%로 포함될 수 있다. 향료의 함량이 0.1 중량% 미만이면 잔향 효과가 현저히 떨어지며, 5 중량%를 초과하면 제형 안정성이 나빠진다.
In the composition of the present invention, fragrances having a ClogP value of 3 or more have high skin retention even after washing and have excellent reverberation properties. In the composition of the present invention, the fragrance having a ClogP value of 3 or more may be included in an amount of 0.1 to 5% by weight, preferably 0.5 to 3% by weight, based on the total weight of the composition. If the content of the fragrance is less than 0.1% by weight, the reverberation effect is remarkably deteriorated, and if it exceeds 5% by weight, the formulation stability is deteriorated.
또한 본 발명은 조성물 총 중량 대비 후박 추출물 0.01~2 중량% 및 지방산 1~ 30 중량%를 포함하며, ClogP 값이 3 이상인 향료를 포함하는 인체 세정용 조성물을 제공한다. 본 발명의 목적상, 상기 특정한 중량비의 성분들의 조합을 포함하는 조성물의 경우 체취 유발 미생물 또는 여드름균에 대한 항균력 및 잔향성이 가장 우수하다.
In addition, the present invention provides a composition for cleansing a human body comprising 0.01 to 2% by weight of a fume extract and 1 to 30% by weight of a fatty acid, and a ClogP value of 3 or more based on the total weight of the composition. For the purposes of the present invention, in the case of a composition comprising a combination of components of the specific weight ratio, the antimicrobial activity and reverberation against a body odor-causing microorganism or acne bacteria are the most excellent.
또한 본 발명의 인체 세정용 조성물은 인체세정 효과, 제형 안정성, 소망하는 효과의 증진, 또는 사용 기호도의 증진을 위해 고급지방산 알칼리염, 계면활성제, 습윤제, 금속이온봉쇄제, 및 정제수 등으로 이루어진 군에서 선택된 1종 이상의 첨가제를 추가로 포함할 수 있다.In addition, the composition for cleaning the human body of the present invention is a group consisting of an alkali salt of a higher fatty acid, a surfactant, a wetting agent, a sequestering agent, and purified water, etc. It may further include one or more additives selected from.
상기 고급지방산 알칼리염은 우수한 세정효과를 제공하는 역할을 할 수 있으며, 이러한 고급지방산으로는 라우르산, 미리스트산, 팔미트산, 스테아르산, 및 올레산 등으로 이루어진 군에서 선택된 하나 이상이 사용될 수 있으나, 이에 한정되는 것은 아니다. 고급 지방산 알칼리염은 조성물 총 중량 대비 5~80 중량%로 포함될 수 있다.The alkali salt of the higher fatty acid may serve to provide an excellent cleaning effect, and as such higher fatty acid, one or more selected from the group consisting of lauric acid, myristic acid, palmitic acid, stearic acid, and oleic acid may be used. However, it is not limited thereto. The higher fatty acid alkali salt may be included in an amount of 5 to 80% by weight based on the total weight of the composition.
상기 계면활성제는 기포 증진제로 사용될 수 있으며, 음이온성 계면활성제, 비이온성 계면활성제, 및 양쪽성 계면활성제 등으로 이루어진 군에서 선택된 하나 이상이 사용될 수 있다. The surfactant may be used as a bubble enhancer, and at least one selected from the group consisting of anionic surfactants, nonionic surfactants, and amphoteric surfactants may be used.
상기 음이온 계면활성제로는 통상적인 화장료 조성물에 사용될 수 있는 것이면 특별히 제한되는 것은 아니며, 지방산 비누(라우린산 나트륨, 팔미틴산 나트륨 등); 고급 알킬 황산 에스테르염(라우릴 황산 나트륨, 라우릴 황산 칼륨 등); 알킬에테르 황산 에스테르염(POE-라우릴 황산 트리에탄올아민, POE-라우릴 황산 나트륨 등); N-아실사르코신산(라우로일사르코신나트륨 등); 고급 지방산 아미드설폰산염(N-미리스토일-N-메틸타우린나트륨, 야자유 지방산 메틸타우리드나트륨, 라우릴메틸타우리드나트륨 등); 인산 에스테르염(POE-올레일에테르인산 나트륨, POE-스테아릴에테르인산 등); 설포숙신산염(디-2-에틸헥실설포숙신산 나트륨, 모노라우로일모노에탄올아미드폴리옥시에틸렌설포숙신산 나트륨, 라우로일폴리프로필렌글리콜설포숙신산 나트륨 등); 알킬벤젠설폰산염(리니어드데실벤젠설폰산 나트륨, 리니어드데실벤젠설폰산 트리에탄올아민, 리니어드데실벤젠설폰산 등); 고급 지방산 에스테르 황산 에스테르염(경화 야자유 지방산 글리세린 황산나트륨 등); N-아실글루타민산염(N-라우로일글루타민산 모노나트륨, N-스테아로일글루타민산 디나트륨, N-미리스토일-L-글루타민산 모노나트륨 등); 황산화유(로트유 등); POE-알킬에테르카르본산; POE-알킬알릴에테르카르본산 염; α-올레핀설폰산염; 고급 지방산 에스테르설폰산염; 2급 알콜황산에스테르염; 고급 지방산 알킬올아미드 황산에스테르염; 라우로일모노에탄올아미드숙신산 나트륨; N-팔미토일아스파라긴산 디트리에탄올아민; 및 카제인나트륨 등으로 이루어진 군에서 선택된 1종 이상 사용될 수 있으나, 이에 한정되는 것은 아니다.The anionic surfactant is not particularly limited as long as it can be used in a conventional cosmetic composition, and fatty acid soap (sodium laurate, sodium palmitate, etc.); Higher alkyl sulfate ester salts (sodium lauryl sulfate, potassium lauryl sulfate, etc.); Alkyl ether sulfate ester salts (POE-lauryl sulfate triethanolamine, POE-lauryl sodium sulfate, etc.); N-acyl sarcosine acid (lauroyl sarcosine sodium, etc.); Higher fatty acid amide sulfonates (N-myristoyl-N-methyltaurine sodium, palm oil fatty acid methyltauride sodium, laurylmethyltauride sodium, etc.); Phosphoric acid ester salts (POE-oleyl ether phosphate sodium, POE-stearyl ether phosphate, etc.); Sulfosuccinate (sodium di-2-ethylhexyl sulfosuccinate, sodium monolauroyl monoethanolamide polyoxyethylene sulfosuccinate, sodium lauroyl polypropylene glycol sulfosuccinate, etc.); Alkylbenzenesulfonates (sodium linear decylbenzenesulfonic acid, triethanolamine linear decylbenzenesulfonic acid, linear decylbenzenesulfonic acid, etc.); Higher fatty acid ester sulfate ester salts (hardened palm oil fatty acid glycerin sodium sulfate, etc.); N-acyl glutamate (N-lauroyl glutamate monosodium, N-stearoyl glutamate disodium, N-myristoyl-L-glutamic acid monosodium, etc.); Sulfated oil (lot oil, etc.); POE-alkylethercarboxylic acid; POE-alkyl allyl ether carboxylic acid salt; α-olefin sulfonate; Higher fatty acid ester sulfonates; Secondary alcohol sulfate ester salt; Higher fatty acid alkylolamide sulfate ester salts; Sodium lauroyl monoethanolamide succinate; N-palmitoylaspartic acid ditriethanolamine; And one or more selected from the group consisting of sodium caseinate and the like may be used, but is not limited thereto.
상기 비이온 계면활성제로는 친유성 비이온 계면활성제 또는 친수성 비이온 계면활성제가 사용될 수 있으며, 통상적인 화장료 조성물에 사용될 수 있는 것이면 특별히 제한되는 것은 아니다, 친유성 비이온 계면 활성제로는 소르비탄 지방산 에스테르류(소르비탄모노올레에이트, 소르비탄모노이소스테아레이트, 소르비탄모노라우레이트, 소르비탄모노팔미테이트, 소르비탄모노스테아레이트, 소르비탄세스퀴올레에이트, 소르비탄트리올레에이트, 펜타-2-에틸헥실산디글리세롤소르비탄, 테트라-2-에틸헥실산 디글리세롤소르비탄 등); 글리세린폴리글리세린 지방산류(모노 면실유 지방산 글리세린, 모노에루카산 글리세린, 세스퀴올레인산 글리세린, 모노스테아린산 글리세린, α,α'-올레인산 피로글루타민산 글리세린, 모노스테아린산 글리세린말산 등); 프로필렌글리콜 지방산 에스테르류(모노스테아린산 프로필렌글리콜 등); 경화 피마자유 유도체; 글리세린알킬에테르 등이, 친수성 비이온 계면활성제로는 POE-소르비탄 지방산 에스테르류(POE-소르비탄모노올레 에이트, POE-소르비탄모노스테아레이트, POE-소르비탄테트라올레에이트 등); POE-소르비트 지방산 에스테르류(POE-소르비트모노라우레이트, POE-소르비트모노올레에이트, POE-소르비트펜타올레에이트, POE-소르비트모노스테아레이트 등); POE-글리세린 지방산 에스테르류(POE-글리세린모노스테아레이트, POE-글리세린모노이소스테아레이트, POE-글리세린트리이소스테아레이트 등); POE-지방산 에스테르류(POE디스테아레이트, POE-모노디올레에이트, 디스테아린산 에틸렌글리콜 등); POE-알킬에테르류(POE-라우릴에테르, POE-올레일에테르, POE-스테아릴에테르, POE-베헤닐에테르, POE-2-옥틸도데실에테르, POE-콜레스탄올에테르 등); 플루로닉형류(플루로닉 등); POE·POP-알킬에테르류(POE·POP-세틸에테르, POE·POP-2-데실테트라데실에테르, POE·POP-모노부틸에테르, POE·POP-수첨 라놀린, POE·POP-글리세린에테르 등); 테트라 POE·테트라 POP-에틸렌디아민 축합물류(테트로닉 등); POE-피마자유 경화 피마자유 유도체(POE-피마자유, POE-경화 피마자유, POE-경화 피마자유 모노이소스테아레이트, POE-경화 피마자유 트리이소스테아레이트, POE-경화 피마자유 모노피로글루타민산 모노이소스테아린산디에스테르, POE-경화 피마자유 말레인산 등); POE 밀랍·라놀린 유도체(POE-소르비트밀랍 등); 알칸올아미드(야자유 지방산 디에탄올아미드, 라우린산 모노에탄올아미드, 지방산 이소프로판올아미드 등); POE-프로필렌글리콜 지방산 에스테르; POE-알킬아민; POE-지방산 아미드; 자당 지방산 에스테르; 알킬에톡 시디메틸아민옥시드; 및 트리올레일인산 등이 있으며, 이들로 이루어진 군에서 선택된 1종 이상 사용될 수 있으나, 이에 한정되는 것은 아니다.As the nonionic surfactant, a lipophilic nonionic surfactant or a hydrophilic nonionic surfactant may be used, and it is not particularly limited as long as it can be used in a conventional cosmetic composition. As the lipophilic nonionic surfactant, sorbitan fatty acid Esters (sorbitan monooleate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesquioleate, sorbitan trioleate, penta-2 -Ethylhexyl diglycerol sorbitan, tetra-2-ethylhexyl diglycerol sorbitan, etc.); Glycerin polyglycerol fatty acids (mono cottonseed oil fatty acid glycerin, monoerucic acid glycerin, sesquioleic acid glycerin, monostearic acid glycerin, α,α'-oleic acid pyroglutamic acid glycerin, monostearic acid glycerin malic acid, etc.); Propylene glycol fatty acid esters (propylene glycol monostearate, etc.); Hydrogenated castor oil derivatives; Examples of the hydrophilic nonionic surfactants such as glycerin alkyl ethers include POE-sorbitan fatty acid esters (POE-sorbitan monooleate, POE-sorbitan monostearate, POE-sorbitan tetraoleate, etc.); POE-sorbit fatty acid esters (POE-sorbit monolaurate, POE-sorbit monooleate, POE-sorbitpentaoleate, POE-sorbit monostearate, etc.); POE-glycerin fatty acid esters (POE-glycerin monostearate, POE-glycerin monoisostearate, POE-glycerin triisostearate, etc.); POE-fatty acid esters (POE distearate, POE-monodioleate, ethylene glycol distearate, etc.); POE-alkyl ethers (POE-lauryl ether, POE-oleyl ether, POE-stearyl ether, POE-behenyl ether, POE-2-octyldodecyl ether, POE-cholestanol ether, etc.); Pluronic type (Pluronic, etc.); POE·POP-alkyl ethers (POE·POP-cetyl ether, POE·POP-2-decyltetradecyl ether, POE·POP-monobutyl ether, POE·POP-hydrogenated lanolin, POE·POP-glycerin ether, etc.); Tetra POE·tetra POP-ethylenediamine condensation products (Tetronic, etc.); POE-castor oil hydrogenated castor oil derivatives (POE-castor oil, POE-cured castor oil, POE-cured castor oil monoisostearate, POE-cured castor oil triisostearate, POE-cured castor oil monopyroglutamic acid monoiso Stearic acid diester, POE-cured castor oil maleic acid, etc.); POE beeswax lanolin derivatives (POE-sorbit beeswax, etc.); Alkanolamides (palm oil fatty acid diethanolamide, lauric acid monoethanolamide, fatty acid isopropanolamide, etc.); POE-propylene glycol fatty acid ester; POE-alkylamine; POE-fatty acid amide; Sucrose fatty acid ester; Alkylethoxydimethylamine oxide; And trioleyl phosphoric acid, and the like, and one or more selected from the group consisting of them may be used, but the present invention is not limited thereto.
또한, 본 발명은 세정력을 보조하고 풍부한 거품을 유지시켜 주기 위해 양쪽성 계면활성제를 함유할 수 있다. 양쪽성 계면활성제는 통상적인 화장료 조성물에 사용될 수 있는 것이면 특별히 제한되는 것은 아니며, 이미다졸린계 양성 계면활성제(2-운데실-N,N,N-(히드록시에틸카르복시메틸)-2-이미다졸린나트륨, 2-코코일-2-이미다졸리늄히드록사이드-1-카르복시에틸옥시2나트륨염 등); 및 베타인계 계면활성제(2-헵타데실-N-카르복시메틸-N-히드록시에틸이미다졸리늄베타인, 라우릴디메틸아미노 아세트산 베타인, 알킬베타인, 아미드베타인, 설포베타인 등) 등으로 이루어진 군에서 선택된 1종 이상이 사용될 수 있으나, 이에 한정되는 것은 아니다.In addition, the present invention may contain amphoteric surfactants to aid in cleaning power and maintain rich foam. Amphoteric surfactants are not particularly limited as long as they can be used in conventional cosmetic compositions, and imidazoline amphoteric surfactants (2-undecyl-N,N,N-(hydroxyethylcarboxymethyl)-2-imide Dazoline sodium, 2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy disodium salt, etc.); And betaine surfactants (2-heptadecyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, lauryldimethylamino acetic acid betaine, alkyl betaine, amide betaine, sulfo betaine, etc.), etc. At least one selected from the group consisting of may be used, but is not limited thereto.
본 발명에서 상기 계면활성제는 조성물 총 중량 대비 0.1~30 중량%로 포함될 수 있다.In the present invention, the surfactant may be included in an amount of 0.1 to 30% by weight based on the total weight of the composition.
상기 습윤제는 세정 후 피부에 보습효과를 부여하기 위해 사용될 수 있으며, 농글리세린, 글리세린, 소르비톨수용액, 비결정성 소르비톨수용액, 폴리에틸렌글리콜류, 및 프로필렌글리콜 등으로 이루어진 군에서 선택된 어느 하나 이상이 사용될 수 있다. 본 발명에서 습윤제는 조성물 총 중량 대비 0.1~20 중량%로 사용될 수 있다.The humectant may be used to impart a moisturizing effect to the skin after washing, and any one or more selected from the group consisting of concentrated glycerin, glycerin, sorbitol aqueous solution, amorphous sorbitol aqueous solution, polyethylene glycol, and propylene glycol may be used. . In the present invention, the humectant may be used in an amount of 0.1 to 20% by weight based on the total weight of the composition.
본 발명의 조성물에서 금속이온봉쇄제는 지방산의 산화 방지를 위해 금속이온을 킬레이팅하여 조성물의 산폐를 억제하는 물질로서, 인산계 화합물과 이디티에이가 사용될 수 있다. 보다 구체적으로, 상기 금속이온봉쇄제는 소듐 포스페이트(Sodium phosphate), 모노소듐 포스페이트(Monosodium phosphate), 디소듐포스페이트(Disodium phosphate), 트리소듐포스페이트(Trisodium phosphate, 테트라소듐에티드로네이트(Tetrasodium etidronate), 소듐트리폴리포스페이트(Sodium tripholyphosphate), 소듐헥사메타포스페이트(Sodium hexametaphosphate), 테트라소듐 피로포스페이트(Tetrasodium pyrophosphate), 소듐애시드 피로포스페이트(Sodium acid pyrophosphate), 디소듐 이디티에이(Disodium EDTA), 및 테트라소듐 이디티에이(Tetrasodium EDTA) 등으로 이루어진 군에서 선택된 하나 이상이 사용될 수 있다. 본 발명에서 금속 이온 봉쇄제는 조성물 총 중량 대비 0.01~0.5 중량%로 사용될 수 있다.In the composition of the present invention, the sequestering agent for metal ions is a material that suppresses dispersal of the composition by chelating metal ions to prevent oxidation of fatty acids, and phosphoric acid-based compounds and EDTA may be used. More specifically, the sequestering agent is sodium phosphate, monosodium phosphate, disodium phosphate, trisodium phosphate, tetrasodium etidronate. , Sodium tripholyphosphate, Sodium hexametaphosphate, Tetrasodium pyrophosphate, Sodium acid pyrophosphate, Disodium EDTA, and Tetrasodium EDTA. One or more selected from the group consisting of Tetrasodium EDTA may be used, etc. In the present invention, the metal ion sequestering agent may be used in an amount of 0.01 to 0.5% by weight based on the total weight of the composition.
본 발명에 따른 인체 세정용 조성물에 있어서, 유효성분으로 작용하는 후박 추출물은 주성분으로 마그놀롤(Magnolol) 및 호노키올(Honokiol)을 약 1:1의 중량비로 포함할 수 있다. 상기 마그놀롤 및 호노키올은 후박 추출물의 총 중량 대비 90 중량% 이상으로 포함될 수 있다.
In the composition for cleansing the human body according to the present invention, the Hubak extract acting as an active ingredient may include Magnolol and Honokiol as main components in a weight ratio of about 1:1. The magnolol and honokiol may be included in an amount of 90% by weight or more, based on the total weight of the extract of Hubak extract.
본 발명에 따른 인체 세정용 조성물은 후박 추출물 및 지방산이 1:10~50(후박 추출물:지방산)의 중량비로 혼합된 혼합물 및 ClogP 값이 3 이상인 향료를 포함할 수 있다. 바람직하게는 상기 중량비는 1:20~40(후박 추출물:지방산)으로 혼합될 수 있다. 상기 혼합물의 1:10(후박 추출물:지방산) 중량비를 기준으로 지방산의 중량비가 미달되는 경우에는 후박 추출물의 피부잔류 농도가 낮아 항균효과의 상승을 기대하기 어렵다. 또한, 상기 혼합물의 1:50(후박 추출물:지방산) 중량비를 기준으로 지방산의 중량비가 초과되는 경우에는 지방산의 변취가 쉽고 기포가 감소하며 향취가 강해 사용이 용이하지 못하다. 또한, 본 발명에 따른 인체 세정용 조성물은 후박 추출물, 지방산, 및 ClogP 값이 3 이상인 향료가 1:10:5 내지 1:50:25의 중량비로 혼합된 혼합물을 포함할 수 있다. 상기 혼합물을 포함하는 조성물은 본 발명의 목적상 유해 세균에 대한 항균력뿐만 아니라 잔향성 또한 현저하게 우수하다.The composition for cleansing the human body according to the present invention may include a mixture of 1:10 to 50 fatty acids and 1:10 to 50 (thick extract: fatty acid), and a fragrance having a ClogP value of 3 or more. Preferably, the weight ratio may be mixed in a ratio of 1:20 to 40 (thick extract: fatty acid). When the weight ratio of fatty acids is less than the 1:10 (thick peel extract: fatty acid) weight ratio of the mixture, it is difficult to expect an increase in the antibacterial effect because the skin residual concentration of the thick peel extract is low. In addition, when the weight ratio of fatty acids is exceeded based on the weight ratio of 1:50 (thick leaf extract: fatty acid) of the mixture, the fatty acid is easily deodorized, bubbles are reduced, and the odor is strong, making it difficult to use. In addition, the composition for cleaning the human body according to the present invention may include a mixture in which the extract, fatty acids, and flavors having a ClogP value of 3 or more are mixed in a weight ratio of 1:10:5 to 1:50:25. The composition comprising the mixture is remarkably excellent not only in antibacterial activity against harmful bacteria, but also in reverberation properties for the purposes of the present invention.
또한 상기 혼합물은 조성물 총 중량 대비 1~35 중량%, 바람직하게는 3~25 중량% 포함될 수 있다. 상기 혼합물이 1 중량% 미만일 경우 항균 효과가 미미하여 원하는 효과를 기대할 수 없고, 35 중량% 초과일 경우 가려움 등 피부자극을 일으킬 수 있으며 제조도 용이하지 못하다.
In addition, the mixture may be included in 1 to 35% by weight, preferably 3 to 25% by weight, based on the total weight of the composition. If the mixture is less than 1% by weight, the antibacterial effect is insignificant and the desired effect cannot be expected. If it is more than 35% by weight, it may cause skin irritation such as itchiness, and manufacturing is not easy.
본 발명에 따른 인체 세정용 조성물은 액취 원인균 및 여드름균에 대한 항균 효과가 우수하다. 보다 구체적으로, 상기 조성물은 액취 원인균인 코리네박테리움 제로시스(Corynebacterium xerosis) 및 여드름균인 프로피오니박테리움 아크네스(Propionibacterium acnes) 등에 대한 증식 억제 및 제거 효과가 우수하여, 체취 제거 및 여드름 치료에 효과적이다.
The composition for cleaning the human body according to the present invention has excellent antibacterial effect against bacteria that cause odor and acne bacteria. More specifically, the composition has excellent proliferation inhibition and removal effects for Corynebacterium xerosis , which is the cause of odor, and Propionibacterium acnes, which is acne bacteria, so that body odor removal and acne treatment It is effective for
또한 본 발명에 따른 인체 세정용 조성물은 사용 편리성을 위한 적절한 제형화를 위하여, 액제, 연고제, 또는 고상 등으로 제조될 수 있다. 보다 구체적으로는 본 발명의 조성물은 화장비누, 바디워시, 세안폼, 샴푸, 린스, 또는 컨디셔너 등의 얼굴, 피부, 또는 모발을 세정하기 위한 제품에 함유될 수 있으나, 이에 한정되는 것은 아니다.
In addition, the composition for cleaning the human body according to the present invention may be prepared in a liquid, ointment, or solid state for proper formulation for ease of use. More specifically, the composition of the present invention may be contained in products for cleaning face, skin, or hair, such as makeup soap, body wash, face wash, shampoo, conditioner, or conditioner, but is not limited thereto.
또한, 본 발명은 후박 추출물을 포함하는 인체 세정용 조성물의 제조 시, 추가적으로 지방산을 첨가함으로써 후박 추출물의 피부 흡착율을 증가시켜 항균 효과가 개선된 인체 세정용 조성물을 제조하는 방법을 제공한다. 상기 방법에서 지방산은 후박 추출물에 결합되어 세정 후 피부 흡착량을 증가시켜 체취 원인균 및 여드름균에 대한 후박 추출물의 항균 효과를 현저하게 증대시킬 수 있다. 상기 방법은 후박 추출물 및 지방산이 1:10~50(후박 추출물:지방산)의 중량비로 혼합된 혼합물 및 ClogP 값이 3 이상인 향료를 포함할 수 있다.In addition, the present invention provides a method of preparing a composition for human body cleaning with an improved antibacterial effect by increasing the skin adsorption rate of the Hubak extract by adding a fatty acid when preparing a composition for cleaning the human body containing the Hubak extract. In the above method, the fatty acid is bound to the Hubak extract to increase the amount of skin adsorption after washing, thereby remarkably increasing the antibacterial effect of the Hubak extract against body odor-causing bacteria and acne bacteria. The method may include a mixture in which the extract and fatty acids are mixed in a weight ratio of 1:10 to 50 (thick extract: fatty acid), and a fragrance having a ClogP value of 3 or more.
본 발명의 인체 세정용 조성물은 액취, 족취, 두취 등의 불쾌감을 주는 체취 유발 미생물들의 증식 억제 및 제거 효과가 탁월하고, 여드름균에 대한 항균력이 우수하여 여드름 치료에 효과적이며, 잔향성이 우수하다. 또한, 본 발명의 인체 세정용 조성물은 천연성분으로 구성되어 인체에 안전하므로, 연령에 관계 없이 피부 건강 유지 및 개선을 위해 사용될 수 있다.The composition for cleaning the human body of the present invention is excellent in inhibiting and removing the proliferation of microorganisms causing unpleasant odors such as liquid odor, foot odor, and head odor, and has excellent antibacterial activity against acne bacteria, so it is effective in treating acne, and has excellent reverberation properties. . In addition, since the composition for cleaning the human body of the present invention is made of natural ingredients and is safe for the human body, it can be used for maintaining and improving skin health regardless of age.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.
Hereinafter, examples, etc. will be described in detail to aid understanding of the present invention. However, the embodiments according to the present invention may be modified in various forms, and the scope of the present invention should not be construed as being limited to the following examples. The embodiments of the present invention are provided to more completely describe the present invention to those of ordinary skill in the art.
본 발명자들은 항균효과가 전체적으로 가장 뛰어난 후박 추출물을 인체세정 기재의 용이한 적용을 위하여 후박 추출물을 ClogP 값이 3 이상인 향에 녹이고, 오일상으로 에몰리언트 효과가 기대되는 지방산을 대상으로 하여, 세정 후 항균효과를 알아보기 위해 일정량의 후박 추출물, 지방산, 및 ClogP 값이 3 이상인 향료를 농도별로 혼합 후 후박 추출물의 피부 잔류 농도를 측정함으로써 인체세정 기재 에서의 항균 효과가 있는지 평가하였다. 그 결과 후박 추출물, 지방산, 및 ClogP 값이 3 이상인 향료가 조합되었을 때, 단독 사용시 보다 높은 후박 추출물의 잔류농도를 확인하였고 이로 인하여 높은 항균효과를 기대할 수 있다. 또한, 오일상의 지방산에 의한 에몰리언트 작용과 잔향 효과로 사용감 또한 우수해진다는 놀라운 사실을 밝혀냈다.
The inventors of the present invention are to dissolve the extract of Fubacco, which has the best antibacterial effect overall, in a fragrance having a ClogP value of 3 or more, and target fatty acids that are expected to have an emollient effect in the form of oil. To find out the effect, a certain amount of Hubak extract, fatty acids, and flavorings having a ClogP value of 3 or more were mixed by concentration, and then the residual skin concentration of the Hubak extract was measured to evaluate whether there was an antibacterial effect in the body cleaning substrate. As a result, when a mixture of Hubak extract, a fatty acid, and a fragrance having a ClogP value of 3 or more, a higher residual concentration of Hubak extract was confirmed when used alone, and a high antibacterial effect can be expected. In addition, it was surprisingly found that the feeling of use is also excellent due to the emollient action and reverberation effect of the oily fatty acid.
제조예: 후박 추출물 제조Preparation Example: Preparation of Humpback Extract
건조된 후박 줄기 껍질을 분말화하고 30~60℃의 온도, 10~30mpa의 압력하에서 CO2 초임계 추출하여, 이를 진공 건조 후 그 추출물을 사용하였다.
The dried thick bark was pulverized and subjected to supercritical extraction of CO 2 under a pressure of 10 to 30 mpa at a temperature of 30 to 60° C., and the extract was used after vacuum drying.
실험예 1: 후박 추출물을 포함한 여러가지 성분의 항균력 평가Experimental Example 1: Evaluation of antimicrobial activity of various components, including the extract of hush
본 발명자들은 생활용품이나 화장품 분야에서 항균효과가 있다고 알려진 약 백여종의 살균제를 대상으로 주요 피부상재균과 액취 및 여드름균에 대한 항균효과를 페이퍼디스크법(Paper Disc법)으로 1차 평가하였다. 그리고, 평가 대상 중, 항균효능이 우수하게 나타난 수종에 대한 정확한 항균력을 평가하기 위하여, 2배 희석법(two fold dilution method)을 이용하여 각각의 균에 대한 최소억제농도(MIC, Minimum Inhibitory Concentration)를 측정하여 그 결과를 하기 표 1(단위:ppm)에 나타냈다. 시험균주로는 피부상재균인 스테필로코커스 에피더미디스(Staphylococcus epidermidis), 액취 원인균인 코리네박테리움 제로시스(Corynebacterium xerosis), 및 여드름균인 프로피오니박테리움 아크네스(Propionibacterium acnes)를 대상으로 시험하였다. MIC 측정방법에서는 항균시료를 액상배지에 일정농도 간격으로 희석하거나 멸균된 고체 배지 내에 일정농도 간격으로 첨가하여 고형화시킨 다음 전배양된 시험균액을 액체배지에 접종시키거나 한 백금이씩 취하여 고체배지 위에 도말한 뒤 37℃에서 24시간 배양한 후 시료 농도별 균체의 성장 정도를 관찰하였다.The present inventors first evaluated the antibacterial effect against major dermatophytes, liquid odors, and acne bacteria with the Paper Disc method, targeting about a hundred kinds of fungicides known to have antibacterial effects in the field of household goods and cosmetics. And, among the evaluation targets, in order to evaluate the exact antimicrobial activity for species with excellent antimicrobial efficacy, the minimum inhibitory concentration (MIC) for each bacteria was determined using the two fold dilution method. It measured and the results are shown in Table 1 (unit: ppm) below. As test strains, the skin flora Staphylococcus epidermidis , odor causative bacteria Corynebacterium xerosis , and acne bacteria Propionibacterium acnes were targeted. Tested. In the MIC measurement method, an antimicrobial sample is diluted in a liquid medium at regular concentration intervals, or added to a sterilized solid medium at regular concentration intervals to solidify, and then the pre-cultured test bacteria are inoculated into the liquid medium, or a platinum dose is taken on the solid medium. After smearing, the cells were incubated at 37°C for 24 hours, and then the degree of growth of the cells according to the sample concentration was observed.
시험결과 후박 추출물이 전체적으로 가장 우수한 항균력을 보였으며, 트리클로산, 트리클로로카반, 베르베린(berberin), 또는 잔토리졸(xanthorrhizol) 등이 우수한 항균력을 보였다. 특히, 코를 자극하는 불쾌취로 강한 냄새 소유자에서 많이 발견되는 것으로 알려져 있는 코리네박테리움 제로시스(Corynebacterium xerosis)균에 대해서는 트리클로산 대비 우수한 항균력을 보여 이 균주에 특이성이 있을 것으로 기대되었다.
As a result of the test, the extract of Hubak extract showed the best antibacterial activity overall, and triclosan, trichlorocarban, berberin, or xanthorrhizol showed excellent antibacterial activity. In particular, Corynebacterium xerosis , which is known to be found in many owners with a strong odor due to an unpleasant odor that irritates the nose, is expected to have excellent antibacterial activity compared to triclosan, and thus have specificity in this strain.
실시예 1~6 및 비교예 1~4의 제조Preparation of Examples 1 to 6 and Comparative Examples 1 to 4
하기 표 2에 기재된 성분과 함량에 따라, 먼저 후박 추출물과 지방산을 ClogP 값이 3 이상인 향료 용액에 용해시키고, 제형이 액상인 경우 인체세정기재에 넣은 후 일반적인 기계식 또는 호모믹서(Homo mixer) 등의 교반기를 이용하여 균일하게 혼합하고, 고형상의 화장비누의 경우에는 비누 베이스(Soap Noodles)를 통상적인 비누 제조 장치를 이용하여 액상 첨가제와 혼합한 후 성형 및 압출 공정을 거쳐 형타하여, 실시예 1~6 및 비교예 1~4의 인체 세정용 조성물을 제조하였다.According to the ingredients and contents shown in Table 2 below, first, the extract and fatty acids are dissolved in a fragrance solution having a ClogP value of 3 or more, and if the formulation is liquid, put it in a human body cleaning material, and then use a general mechanical or homomixer, etc. Mixing uniformly using a stirrer, and in the case of solid cosmetic soap, soap bases (Soap Noodles) were mixed with liquid additives using a conventional soap manufacturing apparatus, and molded through molding and extrusion processes, and Example 1 A composition for cleaning the human body of ~ 6 and Comparative Examples 1 to 4 was prepared.
상기의 인체세정기재는 고급지방산 알칼리염, 계면활성제, 습윤제, 금속이온 봉쇄제, 및 정제수가 1종 이상 적당량 혼합된 세정 베이스를 사용하였다.As the body cleaning material, a cleaning base in which an appropriate amount of one or more kinds of purified water was mixed with an alkali salt of a higher fatty acid, a surfactant, a wetting agent, a sequestering agent, and purified water was used.
중량%unit:
weight%
(제조사:
Wilmar)Soap Noodles
(manufacturer:
Wilmar)
(ClogP 3.0 이상)Spices
(ClogP 3.0 or higher)
실험예 2: 후박 추출물 흡착량 측정Experimental Example 2: Measurement of adsorption amount of thick-baked extract
실시예 1~6 및 비교예 1~4의 인체세정 조성물에 대한 후박 추출물의 피부흡착량 평가를 위해 먼저 제조된 인체세정 조성물에 증류수를 가하여 10% 농도의 용액을 만들어 시료로 하였다. 먼저 헤어리스 마우스(hairless mouse)(5~7주령, 수컷)으로부터 동일부위의 피부를 확보하고 흡착셀(Adsorption cell)에 각질층이 위로 향하게 하고 날카로운 칼을 이용하여 털을 제거한 후 흡착셀을 세이커(shaker)위에 위치시켰다. 시험물질 30g을 흡착셀의 윗부분에 가한 후 세이커를 30초간 120rpm의 속도로 작동시켜 시험물질과 피부의 물리적인 접촉을 발생시켰다. 이때 접촉되는 피부의 면적은 10cm2이다. 곧이어 흡착셀을 기울여 시험물질을 즉시 따라낸 후 셀을 30초간 뒤집어 놓아 유동층을 제거했다. 25℃의 정제수 50g을 가한 후 120rpm의 속도로 30초간 흔들고 흡착셀을 기울여 마찬가지로 유동층을 제거했다. 이러한 세척과정을 동일한 방법으로 5회 반복했다. 피부를 분리하여 펼친 후 직경 10mm의 생체용 펀치(Biopsy Punch)를 이용하여 피부를 동일 크기로 자른 후, 시험튜브에 5조각 넣고 1g의 에탄올을 가한 후 24시간 방치시켜 충분히 용출시키고 볼텍싱(vortexing), 필터링(filtering) 과정을 거쳐 액체 크로마토그래프법을 이용하여 후박 추출물의 정량분석을 실시하였다. 사용된 헤어리스 마우스는 시료당 3마리씩 실시하여 평균값을 구하였으며 단위면적당 흡착량(ug/cm2) 및 하기식 2의 피부 흡착율을 구하여 그 결과를 표 3에 나타내었다.In order to evaluate the skin adsorption amount of Hubak extract for the human body cleaning compositions of Examples 1 to 6 and Comparative Examples 1 to 4, distilled water was added to the first prepared body cleaning composition to prepare a solution having a concentration of 10% and used as a sample. First, secure the skin of the same area from a hairless mouse (5~7 weeks old, male), place the stratum corneum upward on the adsorption cell, remove the hair with a sharp knife, and then set the adsorption cell in a shaker. placed on the (shaker). After 30 g of the test substance was added to the upper part of the adsorption cell, the shaker was operated at a speed of 120 rpm for 30 seconds to cause physical contact between the test substance and the skin. At this time, the area of the skin in contact is 10cm 2 . Immediately, the adsorption cell was tilted to immediately decant the test material, and the cell was turned over for 30 seconds to remove the fluidized bed. After adding 50 g of purified water at 25° C., the fluidized bed was removed by shaking at a speed of 120 rpm for 30 seconds and tilting the adsorption cell. This washing process was repeated 5 times in the same way. After separating and spreading the skin, cut the skin into the same size using a biopsy punch with a diameter of 10 mm, put 5 pieces in a test tube, add 1 g of ethanol, and leave for 24 hours to sufficiently elute and vortexing. ), filtering (filtering) was carried out by using a liquid chromatograph method to quantitative analysis of the extract. The hairless mice used were subjected to three per sample to obtain an average value, and the adsorption amount per unit area (ug/cm 2 ) and the skin adsorption rate of the following formula 2 were obtained, and the results are shown in Table 3.
(68.6%)12.0
(68.6%)
(71.4%)28.9
(71.4%)
(65.5%)35.2
(65.5%)
(53.3%)0.8
(53.3%)
(47.9%)17.5
(47.9%)
(65.8%)7.5
(65.8%)
(74.1%)18.9
(74.1%)
(71.6%)51.2
(71.6%)
(56.0%)6.1
(56.0%)
(48.4%)10.9
(48.4%)
(57.1%)10.0
(57.1%)
(57.3%)23.2
(57.3%)
(54.6%)29.3
(54.6%)
(40.0%)0.6
(40.0%)
(37.5%)13.7
(37.5%)
(55.3%)6.3
(55.3%)
(59.6)15.2
(59.6)
(55.2%)39.5
(55.2%)
(40.4%)4.4
(40.4%)
(38.7%)8.7
(38.7%)
상기의 결과를 보면 비교예 1~4 대비 후박 추출물, 지방산, 및 ClogP 3 이상 향료가 1:10:5 내지 1:50:25의 중량비로 혼합된 실시예 1~6에서 세척 후 후박 추출물의 흡착량이 상대적으로 우수하였다.
Looking at the above results, compared to Comparative Examples 1 to 4, in Examples 1 to 6, in which the mixture of Hubak extract, fatty acid, and ClogP 3 or more in a weight ratio of 1:10:5 to 1:50:25, adsorption of the Hubak extract after washing The amount was relatively excellent.
실험예 3: 액취 및 미생물 억제 임상실험Experimental Example 3: Liquid odor and microbial inhibition clinical test
상기의 실시예 2, 5 및 비교예 2, 4의 인체 세정용 조성물을 직접 겨드랑이에 사용한 후, 항균 및 소취 정도를 평가하였다. 항균은 이지 스탬프(Easy stamp)를 이용하여 겨드랑이로부터 채취한 미생물의 균수를 측정하였고, 소취 정도는 겨드랑이에서 나는 냄새를 직접 맡아 평가하였다. 각각의 자세한 설명은 다음과 같다.After using the composition for cleaning the human body of Examples 2 and 5 and Comparative Examples 2 and 4 directly on the armpit, the degree of antibacterial and deodorant was evaluated. For antibacterial, the number of microorganisms collected from the armpit was measured using an Easy stamp, and the degree of deodorization was evaluated by directly smelling the odor from the armpit. Each detailed description is as follows.
(피평가자 선정 및 시험프로토콜)(Selection of subject and test protocol)
평소에 땀이 많거나 겨드랑이 냄새가 자각적 또는 타각적으로 심하다고 느끼는 20세 이상의 성인남자 20명으로 하였으며, 시험시작 전 일정기간과 시험기간 중 제공된 비누로 겨드랑이를 세정하는 것을 제외하고 통상의 제한 소취제, 화장품, 향수류 등 시험에 영향을 줄 수 있는 제품을 평가부위에 사용하지 않는 것에 동의한 사람으로 한정하였다. 평가시작 전 겨드랑이의 균수 및 냄새를 측정하여 제품 사용후의 베이스라인(baseline)으로 사용하였다. 평가기간은 2주간으로 하였으며 좌우측을 대칭으로 한쪽엔 실시예 2와 5를, 다른 한쪽에는 비교예 2와 4을 각각 사용하도록 하였으며, 각각 10명씩 랜덤하게 제품 좌우 위치를 바꿔서 실시하였다. 사용은 시험기간 동안 매일 한번씩 방문하여 동일시간에 샤워를 실시토록 하였으며, 1주일에 한번씩 마지막 사용 후, 4시간이 경과하여 미생물 측정 및 냄새평가를 실시하였다(겨드랑이 미생물 균수측정).Twenty adult men over 20 years of age who feel that they have a lot of sweat or the odor of their armpits is self-consciously or intentionally. It was limited to those who agreed not to use products that may affect the test, such as cosmetics and perfumes, in the evaluation site. Before the start of the evaluation, the number of bacteria and odor in the armpit were measured and used as a baseline after product use. The evaluation period was 2 weeks, and Examples 2 and 5 were used on one side and Comparative Examples 2 and 4 on the other side, respectively, with the left and right sides symmetrically, and 10 people were carried out by randomly changing the left and right positions of the product. The use was visited once every day during the test period to take a shower at the same time, and after the last use once a week, 4 hours elapsed, and microbial measurement and odor evaluation were performed (armpit microbial count).
이지 스탬프 TPC(Easy stamp TPC)(Komed, Korea)를 이용, 겨드랑이에서 직접 채취하여 미생물 균수를 측정하였다. 사용방법은, 1) 뚜껑이 벗겨지지 않도록 한 개씩 상하로 꺾은 후, 2) 피시험자 명, 날짜 등을 기록하고, 3) 이지 스탬프의 뚜껑을 열고 겨드랑이의 오목한 부분을 가볍게 눌러 찍고, 4) 뚜껑이 잘 닫혀있는지를 확인한 후 37℃ 배양기에 넣어 24시간 이상 배양하였다. 그 결과는 표 4와 같은 방법에 따라 형성된 집락수를 스코어링 스케일(scoring scale)에 따라 0-5점으로 판정하여 시험 전 측정된 집락수와 비교하여 평균값을 구하였다.Using Easy stamp TPC (Komed, Korea), the number of microorganisms was measured by collecting directly from the armpit. To use, 1) bend the lid up and down one by one so that the lid does not come off, 2) record the subject name and date, 3) open the lid of the easy stamp and lightly press the concave part of the armpit, 4) the lid After checking whether it is well closed, it was placed in an incubator at 37°C and incubated for more than 24 hours. As a result, the number of colonies formed according to the method shown in Table 4 was determined as 0-5 points according to the scoring scale, and the average value was obtained by comparing with the number of colonies measured before the test.
1
2
3
4
50
One
2
3
4
5
30-300 colonies (30-300 콜로니)
> 300 colonies. Colonies distinct (300마리 이상, 단 콜로니간 구분명확)
Some but all colonies fused (콜로니간 일부분만 구분 안됨)
Growth not completely confluent (콜로니간 일부분만 구분됨)
Confluent growth (콜로니간 구분 안됨)less than 30 colonies
30-300 colonies (30-300 colonies)
> 300 colonies. Colonies distinct (more than 300, but clear distinction between colonies)
Some but all colonies fused
Growth not completely confluent (only part of colonies are separated)
Confluent growth (no distinction between colonies)
실험 결과는 하기의 표 5에 나타내었다.The experimental results are shown in Table 5 below.
(Baseline)Before use
(Baseline)
(감소율)after use
(Reduction rate)
(62.9%)1.48
(62.9%)
(38.6%)2.32
(38.6%)
(66.1%)1.32
(66.1%)
(39.3%)2.35
(39.3%)
상기의 결과를 보면, 실시예 2, 5의 경우 비교예 2, 4 대비 미생물 집락수가 현저하게 감소했음을 알 수 있다.
From the above results, it can be seen that in Examples 2 and 5, the number of microbial colonies was significantly reduced compared to Comparative Examples 2 and 4.
실험예 4: 냄새강도 측정Experimental Example 4: Measurement of odor intensity
잘 훈련된 관능평가 전문요원 5명이 겨드랑이의 냄새 강도를 직접 맡는 스니프 테스트(sniff test)를 행하였다. 평가는 환기가 되는 항온 항습실에서 실시하였으며 겨드랑이로부터 10cm 이내의 거리에서 직접 코로 냄새를 맡았다. 그 결과는 하기 표 6과 같은 스코어링 스케일에 따라 0-5점으로 시험 전 측정정도와 비교하여 평균값을 구하였다.Five well-trained sensory evaluation specialists conducted a sniff test in which the odor intensity of the armpits was directly detected. The evaluation was conducted in a ventilated constant temperature and humidity room, and the smell was directly sniffed within 10 cm from the armpit. The results were 0-5 points according to the scoring scale shown in Table 6 below, and the average value was calculated by comparing with the measurement accuracy before the test.
1
2
3
4
50
One
2
3
4
5
냄새가 매우 약함
냄새가 약함
냄새가 보통
냄새가 강함
냄새가 매우 강함No smell at all
Very weak smell
Weak smell
Smell is usually
Strong smell
Very strong smell
실험 결과는 하기의 표 7에 나타내었다.The experimental results are shown in Table 7 below.
(Baseline)Before use
(Baseline)
(감소율)after use
(Reduction rate)
(60.3%)1.57
(60.3%)
(37.5%)2.43
(37.5%)
(61.0%)1.49
(61.0%)
(37.7%)2.41
(37.7%)
상기의 결과를 볼때, 본 발명에 따라 제조된 실시예 2, 5는 비교예 2, 4에 비해 현저한 체취 감소 효과가 있음을 알 수 있었다.From the above results, it was found that Examples 2 and 5 prepared according to the present invention had a remarkable effect on reducing body odor compared to Comparative Examples 2 and 4.
결과적으로, 본 발명의 인체 세정용 조성물(실시예 2, 5)은 후박 추출물과 함께 팜유/팜핵유를 함유함으로써 팜유/팜핵유를 함유하지 않은 비교예 2, 4에 비해 미생물의 번식 억제 및 체취 억제 효과가 현저하게 우수한 것을 확인하였다.
As a result, the composition for cleaning the human body of the present invention (Examples 2 and 5) contained palm oil/palm kernel oil together with the extract of husks, thereby inhibiting the reproduction of microorganisms and body odor compared to Comparative Examples 2 and 4 not containing palm oil/palm kernel oil. It was confirmed that the inhibitory effect was remarkably excellent.
실험예 5: 여드름 개선 임상시험Experimental Example 5: Clinical trial for improving acne
실시예 2, 5 및 비교예 1, 3의 여드름 예방 및 치료에 관한 임상효과를 평가하기 위하여 다음과 같은 실험을 실시하였다.In order to evaluate the clinical effect on the prevention and treatment of acne in Examples 2 and 5 and Comparative Examples 1 and 3, the following experiment was conducted.
먼저, 10 후반 ~ 20대 후반의 남성 실험군(실시예 2, 5 사용) 각 10명과, 대조군(비교예 1, 3 사용) 각 10 명을 피시험자로 선정하고, 1일 2회, 2주동안 나누어준 비누를 사용하도록 하여 여드름 예방 및 개선 효과를 평가하였다. 판정 방법은 실험 시작 전에 여드름의 상태에 따라 일정한 등급을 매긴 후, 육안 관찰을 통하여 하기 표 8에 기재된 기준에 따라 면포 감소 효과를 판정한 다음, 임상실험 대상자의 여드름에 대한 등급이 3등급 이상의 감소를 나타내면 효과 우수, 1 ~ 2의 감소를 나타내면 효과 중간, 감소가 나타나지 않으면 효과 없음, 시험 전의 등급보다 시험 후의 등급이 높으면 악화되는 것으로 판정하여 그 결과를 표 8에 나타냈다.First, 10 male experimental groups (using Examples 2 and 5) and 10 each of the control groups (using Comparative Examples 1 and 3) were selected as test subjects, twice a day, for 2 weeks. We evaluated the effect of preventing and improving acne by using the soap provided. The determination method is to determine the effect of reducing comedones according to the criteria shown in Table 8 below through visual observation after a certain grade is given according to the condition of acne before the start of the experiment, and then the grade for acne of the clinical trial subject is reduced by 3 or more. When it shows excellent effect, if it shows a decrease of 1 to 2, it is determined that the effect is intermediate, if there is no decrease, it is not effective, and if the grade after the test is higher than the grade before the test, it is judged to be deteriorated, and the results are shown in Table 8.
1
2
3
4
5
6
7
8
90
One
2
3
4
5
6
7
8
9
면포의 수나 크기가 매우 작거나 염증이 진행되지 않은 것
면포의 수나 크기가 중간 정도로 염증이 진행되지 않은 것
작은 수의 염증성 구진이 존재하는 면포
작고 광범위한 결절 및 염증성 면포가 존재
작은 수 및 크기의 구진성 결절이 존재
중간 정도의 염증성 결절이 존재
많은 수의 염증성 결절이 존재
심한 결절성 면포가 존재
심한 낭포 및 염증성 결절이 존재Normal state
The number or size of comedones is very small or inflammation has not progressed
The number or size of comedones is moderately inflamed
Comedones with a small number of inflammatory papules
Small, extensive nodules and inflammatory comedones are present
Small number and size of papular nodules present
Moderate inflammatory nodules present
The presence of a large number of inflammatory nodules
Presence of severe nodular comedones
Severe cysts and inflammatory nodules present
실험 결과는 하기의 표 9에 나타내었다.The experimental results are shown in Table 9 below.
상기 표 9에 나타난 바와 같이, 후박 추출물을 0.2 중량%(실시예 2) 또는 0.1 중량%(실시예 5) 포함하는 인체 세정용 조성물은 후박 추출물을 0.005 중량%(비교예 1) 또는 0.003 중량%(비교예 3) 포함하는 인체 세정용 조성물 보다 여드름 개선 효과가 현저하게 우수한 것으로 나타났다.
As shown in Table 9, the composition for cleaning the human body containing 0.2% by weight (Example 2) or 0.1% by weight (Example 5) of the red pepper extract contained 0.005% by weight (Comparative Example 1) or 0.003% by weight of the red pepper extract. (Comparative Example 3) It was found that the acne improvement effect was remarkably superior to that of the composition for cleaning the human body containing.
이상 4가지 실험을 통하여, 본 발명에 따른 후박 추출물, 지방산, 및 ClogP 값이 3 이상인 향료를 함유하는 인체 세정용 조성물은 체취균과 여드름균에 강력한 항균 효과를 나타내는 것을 확인하였다. 또한 상기 조성물은 세정 후에도 피부 흡착 정도가 커 소량 사용이 가능하며, 피부에 대한 부작용이 적고, 에몰리언트 효과 부여로 피부 건강을 효과적으로 유지 및 개선시킬 수 있음을 확인하였다.Through the above four experiments, it was confirmed that the composition for cleaning the human body containing the extract, fatty acid, and fragrance having a ClogP value of 3 or more according to the present invention exhibits a strong antibacterial effect on body odor and acne bacteria. In addition, it was confirmed that the composition can be used in a small amount due to its high degree of skin adsorption even after washing, has few side effects to the skin, and can effectively maintain and improve skin health by imparting an emollient effect.
Claims (12)
[수학식 1]
상기 후박 추출물 및 지방산이 1:10~50(후박 추출물:지방산)의 중량비로 혼합된 혼합물을 포함하는 인체 세정용 조성물.Including a scented extract, a fatty acid, and a fragrance having a ClogP (octanol-water partition coefficient) value of 3 or more according to the following Equation 1,
[Equation 1]
A composition for cleaning the human body comprising a mixture in which the extract and fatty acids are mixed in a weight ratio of 1:10 to 50 (thick extract: fatty acid).
[수학식 1]
According to claim 1, wherein the composition is a fragrance having a value of 3 or more of ClogP (octanol-water partition coefficient) according to the following Equation 1, 1:10:5 to 1: A composition for cleansing the human body comprising a mixture mixed in a weight ratio of 50:25 (fume extract: fatty acid: fragrance).
[Equation 1]
추가적으로 지방산을 첨가함으로써 후박 추출물의 피부 흡착율을 증가시켜 항균 효과가 개선된 인체 세정용 조성물의 제조 방법에 있어서,
상기 인체 세정용 조성물은 후박 추출물 및 지방산이 1:10~50(후박 추출물:지방산)의 중량비로 혼합된 혼합물 및 하기 수학식 1에 의한 ClogP(옥탄올-물 분배계수, Octanol-water partition coefficient) 값이 3 이상인 향료를 포함하는 인체 세정용 조성물의 제조 방법.
[수학식 1]
In the manufacture of a composition for cleaning the human body containing the extract,
In the method for preparing a composition for cleaning the human body with improved antibacterial effect by increasing the skin adsorption rate of the extract from the husks by adding additional fatty acids,
The composition for cleaning the human body is a mixture of 1:10 to 50 (thick extract: fatty acid) in a mixture of thick peel extract and fatty acid, and ClogP (octanol-water partition coefficient) according to Equation 1 below. A method for producing a composition for cleaning a human body comprising a fragrance having a value of 3 or more.
[Equation 1]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20140029169 | 2014-03-12 | ||
KR1020140029169 | 2014-03-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150106804A KR20150106804A (en) | 2015-09-22 |
KR102236391B1 true KR102236391B1 (en) | 2021-04-05 |
Family
ID=54245529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140109935A Expired - Fee Related KR102236391B1 (en) | 2014-03-12 | 2014-08-22 | Personal cleansing composition comprising Magnolia officinalis extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102236391B1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200360260A1 (en) | 2017-12-15 | 2020-11-19 | Conopco, Inc., D/B/A Unilever | Topical composition comprising antimicrobial lipid |
KR102477448B1 (en) * | 2020-05-21 | 2022-12-14 | 유비에스아이엔씨 주식회사 | Shower filter composition including natural oriental herb material and the shower head structure including the composition |
CN113171322B (en) * | 2021-05-12 | 2022-04-19 | 广东中科卓原生物科技有限公司 | Acne-removing composition, application thereof and acne-removing nano gel emulsion containing acne-removing composition |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101116852B1 (en) * | 2007-05-31 | 2012-03-06 | 주식회사 바이오랜드 | Composition comprising an extract of Magnolia officinalis Rehd. et Wils. or 4-O-methylhonokiol isolated therefrom having anti-inflammatory, anti-allergy and anti-wrinkle activity |
KR100971269B1 (en) * | 2008-02-15 | 2010-07-20 | 주식회사 유니젠 | Processed thick gourd extract and antimicrobial composition containing the same |
JP5536086B2 (en) * | 2009-10-06 | 2014-07-02 | ライオン株式会社 | Liquid skin cleanser composition |
KR101293066B1 (en) * | 2011-02-11 | 2013-08-07 | 더마텍코리아(주) | A functional composition with pharmacological activity and a cosmetic composition, an oral cleansing composition and a hair care composition comprising the same |
-
2014
- 2014-08-22 KR KR1020140109935A patent/KR102236391B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20150106804A (en) | 2015-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101985354B1 (en) | A composition comprising a herbal fermentation extract having preventing and improving acne lesion | |
CN112048402B (en) | A kind of underwear soap with antibacterial, stain removal and peculiar smell and preparation method thereof | |
KR20190081558A (en) | Cosmetic composition comprising liposome for enhancing skin barrier function | |
CN103860427B (en) | A kind of moisturizing shower glue | |
KR102236391B1 (en) | Personal cleansing composition comprising Magnolia officinalis extract | |
CN110613632A (en) | Pet washing and caring composition rich in hyaluronic acid or salt thereof and preparation method thereof | |
KR20090073621A (en) | Hypoallergenic face wash powder containing mung bean powder | |
KR101565716B1 (en) | Natural soap and preparation method thereof | |
JP6283156B2 (en) | Diketone action inhibitor | |
KR101308959B1 (en) | Low-Irritative Powder Composition for Washing | |
JP5695678B2 (en) | Deodorant containing polyhydric alcohol | |
JP6651104B1 (en) | Method for producing external composition | |
KR102271989B1 (en) | Preparation method of chamaecyparis obtusa essential oil extract and antimicrobial composition comprising thereof | |
JP7316666B2 (en) | Cleansing composition and method for producing same | |
JP4546790B2 (en) | Lower fatty acid production inhibitor that does not sterilize skin resident bacteria | |
JP6025442B2 (en) | Diketone action inhibitor | |
KR101185435B1 (en) | Preparing method of beauty treatment including curcuma longa linne extract for old people | |
JP6586506B1 (en) | Topical skin preparation | |
KR100536550B1 (en) | Composition containing moutan root bark extract as active ingredient | |
JP4660088B2 (en) | Deodorant and deodorant composition, cosmetic composition and cleaning composition containing the deodorant | |
JP7705163B2 (en) | Cleansing compositions and methods for producing same | |
JP2008169196A (en) | Skin preparation | |
RU2799443C2 (en) | Hair and scalp cleaner and care | |
KR102718114B1 (en) | Composition for inhibiting body odor, serum secretion, and dandruff comprising Lagerstroemia indica extracts as an active ingredient | |
RU2810088C1 (en) | Method of obtaining universal detergent for washing hands and dishes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20140822 |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20190722 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20140822 Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20201123 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20210322 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20210330 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20210330 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20250110 |